Linda A. Johnson

Patients in poor countries struggle despite low prices


TRENTON, N.J. — Cancer drugs predictably cost much more in the U.S. than in poor countries and even other wealthy nations, but... Read more

Pfizer buying skin drug maker Anacor for $5.2 billion


TRENTON, N.J. — Pfizer is fortifying its key immunology and inflammation drug business, snapping up a small maker of skin... Read more

Valeant files overdue financial report, ending debt default

Valeant Pharmaceuticals resolved its default on some of its $30 billion in debt by finally filing its long-overdue U.S. financial report... Read more

Jury orders Gilead to pay $200 million to Merck

The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages... Read more

Drugmaker Valeant reveals SEC inquiry


Valeant Pharmaceuticals is entangled in an SEC investigation that compounds the drugmaker’s headaches as it grapples with... Read more

Drugmaker Shire to acquire Baxalta

TRENTON, N.J. — Irish drugmaker Shire PLC’s second attempt to buy Baxalta looks more likely to succeed, with Baxalta’s board backing the... Read more